256 related articles for article (PubMed ID: 36278224)
1. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis.
Vassilopoulos A; Shehadeh F; Benitez G; Kalligeros M; Cunha JS; Cunha CB; Mylonakis E
Front Pharmacol; 2022; 13():992713. PubMed ID: 36278224
[No Abstract] [Full Text] [Related]
2. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
[TBL] [Abstract][Full Text] [Related]
3. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.
Kourbeti IS; Ziakas PD; Mylonakis E
Clin Infect Dis; 2014 Jun; 58(12):1649-57. PubMed ID: 24647016
[TBL] [Abstract][Full Text] [Related]
5. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
6. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
8. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
9. Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis.
Chiu HY; Hung YT; Huang SW; Huang YH
Ther Adv Chronic Dis; 2022; 13():20406223221091188. PubMed ID: 35519434
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
[No Abstract] [Full Text] [Related]
11. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
12. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review.
Winthrop K; Isaacs J; Calabrese L; Mittal D; Desai S; Barry J; Strengholt S; Galloway J
Semin Arthritis Rheum; 2023 Feb; 58():152120. PubMed ID: 36347212
[TBL] [Abstract][Full Text] [Related]
13. Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study.
Takabayashi K; Ando F; Ikeda K; Nakajima H; Hanaoka H; Suzuki T
Mod Rheumatol; 2023 Nov; 33(6):1078-1086. PubMed ID: 36308397
[TBL] [Abstract][Full Text] [Related]
14. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
Gialouri CG; Evangelatos G; Fragoulis GE
Mediterr J Rheumatol; 2022 Mar; 33(Suppl 1):150-161. PubMed ID: 36127928
[TBL] [Abstract][Full Text] [Related]
15. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
[TBL] [Abstract][Full Text] [Related]
16. Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Navarini L; Currado D; Costa L; Tasso M; Chimenti MS; Caso F
J Exp Pharmacol; 2020; 12():487-502. PubMed ID: 33235521
[TBL] [Abstract][Full Text] [Related]
17. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
18. Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Chakravarty SD; McLean RR; Blachley T; Kawashima T; Lin I; Kavanaugh A; Ogdie A
ACR Open Rheumatol; 2022 May; 4(5):447-456. PubMed ID: 35218320
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Sequential Lines of Biologic and Targeted Small Molecule Drugs in Psoriatic Arthritis: A Systematic Review.
Gollins CE; Vincent R; Fahy C; McHugh N; Brooke M; Tillett W
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38243715
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.
Pehlivan Ö; Aydin T
Ann Saudi Med; 2022; 42(3):155-164. PubMed ID: 35658585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
